{"id":"https://openalex.org/W2005215075","doi":"https://doi.org/10.1002/ddr.430300303","title":"Surviving as a niche player in the pharmaceutical industry: Reflections from the field","display_name":"Surviving as a niche player in the pharmaceutical industry: Reflections from the field","publication_year":1993,"publication_date":"1993-11-01","ids":{"openalex":"https://openalex.org/W2005215075","doi":"https://doi.org/10.1002/ddr.430300303","mag":"2005215075"},"language":"en","primary_location":{"id":"doi:10.1002/ddr.430300303","doi":"https://doi.org/10.1002/ddr.430300303","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ddr.430300303","pdf_url":null,"source":{"id":"https://openalex.org/S26306840","display_name":"Drug Development Research","issn_l":"0272-4391","issn":["0272-4391","1098-2299"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Development Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016548138","display_name":"Stig W. J\u00f8rgensen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128558","display_name":"Coloplast (Denmark)","ror":"https://ror.org/03m91y692","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210128558"]}],"countries":["DK"],"is_corresponding":true,"raw_author_name":"Stig Jorgensen","raw_affiliation_strings":["Coloplast, Humlebaek Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Coloplast, Humlebaek Denmark","institution_ids":["https://openalex.org/I4210128558"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110169041","display_name":"Ivan Jensen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Ivan Jensen","raw_affiliation_strings":["Regulatory Affairs, Diabetes Care Division, Novo Nordisk, Bagsvaerd Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Regulatory Affairs, Diabetes Care Division, Novo Nordisk, Bagsvaerd Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052326591","display_name":"Martin P. Edwards","orcid":"https://orcid.org/0009-0006-1060-7035","observed_orcids":["https://orcid.org/0009-0006-1060-7035"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martin Edwards","raw_affiliation_strings":["Medical Affairs, Zymogenetics, Inc., Seattle, Washington"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs, Zymogenetics, Inc., Seattle, Washington","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5016548138"],"corresponding_institution_ids":["https://openalex.org/I4210128558"],"apc_list":{"value":3980,"currency":"USD","value_usd":3980},"apc_paid":null,"fwci":2.2874,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.89071815,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"3","first_page":"112","last_page":"120"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.8154000043869019,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.8154000043869019,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T13151","display_name":"Business Strategies and Innovation","score":0.12070000171661377,"subfield":{"id":"https://openalex.org/subfields/1408","display_name":"Strategy and Management"},"field":{"id":"https://openalex.org/fields/14","display_name":"Business, Management and Accounting"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12851","display_name":"Firm Innovation and Growth","score":0.02710000053048134,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pharmaceutical-industry","display_name":"pharmaceutical industry","score":0.8730000257492065},{"id":"https://openalex.org/keywords/small-pharmaceutical-companies","display_name":"small pharmaceutical companies","score":0.6389999985694885},{"id":"https://openalex.org/keywords/business-survival","display_name":"business survival","score":0.593999981880188},{"id":"https://openalex.org/keywords/strategic-management","display_name":"strategic management","score":0.6150000095367432},{"id":"https://openalex.org/keywords/innovation","display_name":"innovation","score":0.5109999775886536},{"id":"https://openalex.org/keywords/risk-taking","display_name":"risk-taking","score":0.7279999852180481},{"id":"https://openalex.org/keywords/technological-frontier","display_name":"technological frontier","score":0.7039999961853027},{"id":"https://openalex.org/keywords/managerial-mindset","display_name":"management mindset","score":0.5429999828338623}],"concepts":[{"id":"https://openalex.org/C153991713","wikidata":"https://www.wikidata.org/wiki/Q17142856","display_name":"Niche","level":2,"score":0.775464653968811},{"id":"https://openalex.org/C9652623","wikidata":"https://www.wikidata.org/wiki/Q190109","display_name":"Field (mathematics)","level":2,"score":0.5905852913856506},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.5869078636169434},{"id":"https://openalex.org/C26271046","wikidata":"https://www.wikidata.org/wiki/Q187097","display_name":"Economic geography","level":1,"score":0.38194870948791504},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.3668311834335327},{"id":"https://openalex.org/C205649164","wikidata":"https://www.wikidata.org/wiki/Q1071","display_name":"Geography","level":0,"score":0.2879457473754883},{"id":"https://openalex.org/C18903297","wikidata":"https://www.wikidata.org/wiki/Q7150","display_name":"Ecology","level":1,"score":0.2610135078430176},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.23425951600074768},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.16703519225120544},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.07794111967086792},{"id":"https://openalex.org/C202444582","wikidata":"https://www.wikidata.org/wiki/Q837863","display_name":"Pure mathematics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1002/ddr.430300303","doi":"https://doi.org/10.1002/ddr.430300303","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ddr.430300303","pdf_url":null,"source":{"id":"https://openalex.org/S26306840","display_name":"Drug Development Research","issn_l":"0272-4391","issn":["0272-4391","1098-2299"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Development Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":4,"referenced_works":["https://openalex.org/W1492301466","https://openalex.org/W1578960547","https://openalex.org/W2006136741","https://openalex.org/W2134940400"],"related_works":["https://openalex.org/W2038664640","https://openalex.org/W1964093187","https://openalex.org/W2478568240","https://openalex.org/W2061928931","https://openalex.org/W2608280576","https://openalex.org/W2049815708","https://openalex.org/W1498082821","https://openalex.org/W2468144475","https://openalex.org/W2029547567","https://openalex.org/W2071840769"],"abstract_inverted_index":{"Abstract":[0],"The":[1],"pharmaceutical":[2],"industry":[3],"can":[4],"be":[5,82],"divided":[6],"into":[7],"a":[8,18,60,100],"top":[9],"tier":[10,20,32],"of":[11,37,84],"about":[12],"30":[13],"major":[14],"league":[15,39],"companies":[16],"and":[17,33,46,51,79],"second":[19,31],"(minor":[21],"league)":[22],"comprising":[23],"several":[24],"thousand.":[25],"This":[26],"paper":[27],"focused":[28],"on":[29,70],"the":[30,34,55,67,71,90],"particular":[35],"challenge":[36],"minor":[38],"companies\u2014especially":[40],"niche":[41,61,101],"players\u2014to":[42],"balance":[43],"operating":[44],"requirements":[45],"strategic":[47],"ambitions":[48],"within":[49],"limited":[50],"limiting":[52],"resources.":[53],"In":[54],"authors'":[56],"experience,":[57],"survival":[58],"as":[59,99],"player":[62],"requires":[63],"not":[64],"only":[65],"that":[66,76],"company":[68],"stays":[69],"technology":[72],"frontier":[73],"but":[74],"also":[75],"risk":[77],"willingness":[78],"innovative":[80],"behavior":[81],"characteristic":[83],"managers'":[85],"mindset.":[86],"To":[87],"this":[88],"end,":[89],"authors":[91],"share":[92],"13":[93],"\u201cground":[94],"rules\u201d":[95],"to":[96],"perform":[97],"appropriately":[98],"player.":[102],"\u00a9":[103],"1993":[104],"wiley\u2010Liss,":[105],"Inc.":[106]},"counts_by_year":[],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2016-06-24T00:00:00"}